- Clinical Trials
- Research News
- Industry Trends
- Agency Actions
- Drug Safety Issues
- Approvals, Launches, & New Indications
- Health Care Reform
Generic Adenoscan (Adenosine Injection) Launched in U.S.
Product is adjunct to myocardial perfusion scintigraphy (September 24)
A generic equivalent to Adenoscan (adenosine injection) has been launched in the U.S. The generic product’s manufacturer (Teva Pharmaceuticals) was the first to file, making the product eligible for 180 days of marketing exclusivity.
Adenoscan is supplied as 20-mL and 30-mL vials and is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.
Marketed by Astellas Pharma, Adenoscan had annual sales of approximately $65 million in the U.S., according to IMS data as of June 30, 2013.
Source: Teva Pharmaceuticals; September 24, 2013.